GlassScriptPhysician profile
Dilip Kumar Jayaraman
NPI 1467860809
$485.42
in general payments reported to CMS, 2019-2025
11 companies · $27.10 in 2025
The $27.10 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $221 · 2023: $36.32 · 2024: $201 · 2025: $27.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $264.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $103.57 | 2024 | Xcopri |
| Abbvie INC. | $95.73 | 2022-2024 | |
| Amgen INC. | $42.23 | 2022-2023 | Aimovig |
| Neurelis, INC. | $39.29 | 2023-2024 | Valtoco |
| Biohaven Pharmaceutical Holding Company LTD. | $38.56 | 2022 | |
| Upsher-Smith Laboratories LLC | $38.03 | 2022 | |
| Merz Pharmaceuticals, LLC | $34.81 | 2022 | |
| Pfizer INC. | $27.10 | 2025 | |
| Depuy Synthes Sales INC. | $26.42 | 2022 | |
| Emd Serono, INC. | $23.45 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Kumar Jayaraman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.